NCT05196477 - Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection | Biotech Hunter

Enrollment

3,087

Participants

Timeline

Start Date

July 14, 2021

Primary Completion Date

August 29, 2022

Study Completion Date

August 29, 2022

Conditions

COVID-19

Interventions

DRUG

Olokizumab

The details of taking olokizumab, including its route of administration, dose and frequency of taking the drug as part of routine clinical practice, will be registered in the electronic case report forms (eCRFs).

DRUG

Standard therapy

Standard treatment (excluding administration of olokizumab, other interleukin (IL) (interleukin-1 and interleukin-17) inhibitors and Janus-kinase inhibitors.

Trial Locations (6)

105187

"State Budgetary Healthcare Institution City Clinical Hospital named after F.I. Inozemtsev of Moscow Healthcare Department", Moscow

170036

"State Budgetary Institution of Healthcare of Tver region Regional clinical hospital", Tver'

197706

"St. Petersburg State Budgetary Healthcare Institution City Hospital No. 40 of the Kurortny District", Saint Petersburg

420012

"Federal State Budgetary Educational Institution of Higher Education Kazan State Medical University under the Ministry of Health of the Russian Federation", Kazan'

450008

Federal State Budgetary Educational Institution of Higher Education Bashkir State Medical University of the Ministry for Healthcare of the Russian Federation, Ufa

454021

"State Budgetary Healthcare Institution Regional Hospital № 3", Chelyabinsk